

Ernst & Young Luncheon

Satellite Event

“Ernst & Young Global Biotechnology Mid-Year Update “

Date: Thursday 29 October 2009

Time: 12:45pm - 2:00pm

Venue: Melbourne Convention and Exhibition Centre

Price: Free for AusBiotech2009 conference delegates

[Click here](#) to register now as numbers are limited.

Overview

This session will look at the global biotech sector six months on from the Ernst & Young *Beyond Borders Global Biotechnology Report 2009*. How has the industry fared in light of the continued global economic turmoil - has the industry rallied and turned to more creative funding models to ensure its long-term survival or has the industry further tumbled into the deep dark hole that has plagued many other industries globally?

Speakers:

- **Scott Sarazen**, Global Biotech Centre Markets Leader, Boston, Ernst & Young
- **Winna Brown**, Australian Biotechnology Leader, Ernst & Young

Scott Sarazen is one of the authors of *Beyond Borders* and has over 20 years' experience in biotech. Scott brings a wealth of insight into the biotech sector, having worked in a variety of strategic roles within the industry prior to joining Ernst & Young, including being the Senior Vice President of Corporate Development at Straumman, North America and the Director of Global Planning and Development at Genzyme Corporation.

Winna Brown is the author of the Australian section of *Beyond Borders* and has over 10 years' experience working with biotechnology companies in Australia, and will discuss the Australian sector.

Background - Ernst & Young *Beyond Borders Global Biotechnology Report 2009*

Launched in May this year, this report confirmed that as a result of the global financial crisis the biotechnology sector was in the midst of a prolonged and systemic funding drought, placing the business model that fuelled biotech growth for the past 33 years, under significant strain. The Report then discussed the four sweeping, paradigm-shifting trends emerging in the global biotech sector, which were expected to lead to new, more sustainable ways of funding drug development: a wave of generic drugs based on today's blockbusters; the expansion of personalised medicine; fundamental healthcare reform in the US; and the continued globalisation of the industry. It was expected that financing would continue to be scarce and consolidation of the industry would continue in the short to medium-term.